Description:
Coronary Heart Disease (CHD) is a heart disorder caused by blockage of blood vessels. CHD can be detected by Myocardial Perfusion Imaging (MPI). MPI is performed by injecting a radiopharmaceutical into the patient's body. 99mTc-sestamibi is a radiopharmaceutical that is commonly used in MPI. Sestamibi is available in the form of a multidose vial, but the cost of the examination will be expensive if it is only used for one patient. Cost effectiveness can be increased by fractionating the sestamibi kit before labelled by 99mTc. 99mTc-sestamibi needs to be tested for quality control before it is administered to the patients. One of the tests is the radiochemical purity test. The aim of this study was to determine the radiochemical purity of the fractionated sestamibi kit labelled by 50 mCi 99mTc. 2 vials of sestamibi kit were fractionated by adding 5 mL of 0.9% NaCl solution to each vial and divided into 10 new vials. Radiochemical purity was measured using the thin layer chromatography (TLC) method. The results of this study indicated that all samples had radiochemical purity of 100% up to 6 hours after labelling.

URL:
http://103.158.96.210:88/web_repository/uploads/33332-147145-4-PB.pdf

Type:
Journal

Document:
Diploma III Farmasi

Date:
23-06-2024

Author:
HASNA CHOERUNISA